스페인의 맘모그래피 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the spain mammography market size is projected to be USD 67.47 million in 2025, USD 72.94 million in 2026, and reach USD 107.78 million by 2031, growing at a CAGR of 8.12% from 2026 to 2031.

This report is Segmented by Product Type (Digital Systems, Breast Tomosynthesis (3-D), and More), End User (Hospitals, Diagnostic Centers, Specialty Clinics, Mobile Screening Units, Breast Imaging Centres), Technology (2-D Mammography, 3-D/DBT, AI-Assisted CAD, Contrast-Enhanced Digital Mammography), and Geography. Market Forecasts are Provided in Terms of Value (USD).

Spain Mammography Market Trends and Insights

Growing Breast-Cancer Incidence in Women 40-69

In 2024, Spain reported 36,395 new breast cancer diagnoses, making it the country's most prevalent malignancy. Catalonia experienced a 16% increase in cases over the past decade. The majority of diagnoses occur among women aged 50-69, aligning with the demographic targeted for biennial screening. Even slight increases in participation can drive system utilization rates beyond 85%. Advocacy efforts are pushing to expand screening age eligibility to 45-74, which could result in an additional 1.5 million screenings annually and require 20-25 more units to maintain wait times under 30 days. Awareness campaigns in October led to a 12% rise in self-referrals in 2024, further straining traditional analog platforms. These factors collectively highlight the growing demand for advanced digital systems.

Expansion of Biennial National Screening

All 17 autonomous communities in Spain invite women aged 50-69 to biennial screenings, but participation rates dropped from 83% in 2017 to 74% in 2020, primarily due to COVID-19-related disruptions. Five regions have extended invitations to women aged 45-49 and 70-74, providing valuable insights for an upcoming EU guideline revision. Real-time tracking by the national Cancer Surveillance System reveals disparities, with foreign-born women and rural residents participating at lower rates. Mobile units are being deployed to address these gaps. For instance, Galicia's mobile fleet increased coverage in towns with fewer than 5,000 residents from 68% to 79% within a year. Similarly, Andalusia's program screened 42,000 women in 2024, reflecting a 15% annual growth.

Radiologist Shortage Delaying AI Validation & Deployment

Prospective AI trials require extensive ground-truth labeling, but Spain's below-average radiologist density poses a significant challenge to this process. Kheiron's Mia algorithm demonstrated a 13% improvement in detection rates and a 25% reduction in interval cancers across three Catalan hospitals. However, broader implementation is contingent on the availability of local validation data. Additionally, the eHealth Network now requires BI-RADS-compliant metadata for cross-border data exchange, necessitating IT system upgrades in hospitals before large-scale AI pilot projects can proceed.

Other drivers and restraints analyzed in the detailed report include:

1. Regional Tenders Accelerating 3-D Tomosynthesis Roll-Out
2. Shift to Personalized, Risk-Based Screening Models
3. Reimbursement Gaps for Tomosynthesis Outside Public Programs

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, Spain's digital mammography market was valued at USD 57.34%, with a projected CAGR of 11.50% through 2031. The AMAT-I fund initiatives are driving the adoption of low-dose, energy-efficient detectors, accelerating the shift from analog systems. Long-term service agreements, such as GE HealthCare's recent contract in Huesca, are increasing switching costs and strengthening the position of established players. While tomosynthesis platforms command a 30-40% price premium, procurement decisions are justified by sensitivity improvements, such as a 15% gain reported by leading hospitals. However, contrast-enhanced digital mammography adoption remains limited due to reimbursement challenges, restricting its use to private networks catering to self-pay patients.

Rising R&D efforts are focusing on detector materials that reduce the average glandular dose by up to 30%, aligning with sustainability goals in healthcare. Vendors are also integrating AI-triage software to streamline workflows by prioritizing high-suspicion cases, enabling radiologists to focus on complex analyses. The market increasingly favors cloud-ready platforms, driven by regional health IT projects requiring Vendor-Neutral Archives to manage tomosynthesis datasets without on-premise servers. With federal funding tied to energy efficiency and cybersecurity compliance, digital systems are expected to continue outpacing analog replacements.

List of Companies Covered in this Report:

1. Agfa-Gevaert
2. Analogic
3. Canon Inc. (Canon Medical Systems)
4. Carestream Health
5. CMR Naviscan Corp.
6. ESAOTE SpA
7. FUJIFILM
8. GE Healthcare
9. General Medical Merate
10. Hologic
11. iCAD Inc.
12. IMS Giotto SpA
13. Incepto Medical Iberia
14. Koninklijke Philips
15. Kubtec Medical Imaging
16. Metaltronica
17. Miwendo Solutions
18. Palex Medical
19. Planmed
20. Samsung Medison Co. Ltd.
21. Sectra
22. Shimadzu
23. Siemens Healthineers

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing Breast-Cancer Incidence in Women 40-69
  • 4.2.2 Expansion of Biennial National Screening
  • 4.2.3 Regional Tenders Accelerating 3-D Tomosynthesis Roll-Out
  • 4.2.4 Shift to Personalised, Risk-Based Screening Models
  • 4.2.5 GDPR-Compliant Cloud PACS Enabling Cross-Facility Teleradiology
  • 4.2.6 Hospital Decarbonisation Goals Favouring Low-Dose, Energy-Efficient Detectors
• 4.3 Market Restraints
  • 4.3.1 Cumulative-Dose Radiation Anxiety Among Younger Cohorts
  • 4.3.2 Reimbursement Gaps for Tomosynthesis Outside Public Programmes
  • 4.3.3 Radiologist Shortage Delaying AI Validation & Deployment
  • 4.3.4 Litigation Over Interval Cancers Diverting Budgets to MRI
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Rivalry

5 Market Size & Growth Forecasts (Value in USD)

• 5.1 By Product Type
  • 5.1.1 Digital Systems
  • 5.1.2 Breast Tomosynthesis (3-D)
  • 5.1.3 Analog Systems
  • 5.1.4 Contrast-Enhanced Digital Mammography
• 5.2 By End User
  • 5.2.1 Hospitals
  • 5.2.2 Diagnostic Centers
  • 5.2.3 Specialty Clinics
  • 5.2.4 Mobile Screening Units
  • 5.2.5 Breast Imaging Centres
• 5.3 By Technology
  • 5.3.1 2-D Mammography
  • 5.3.2 3-D / DBT
  • 5.3.3 AI-Assisted CAD
  • 5.3.4 Contrast-Enhanced Digital Mammography

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 Agfa-Gevaert Group
  • 6.3.2 Analogic Corporation
  • 6.3.3 Canon Inc. (Canon Medical Systems)
  • 6.3.4 Carestream Health Inc.
  • 6.3.5 CMR Naviscan Corp.
  • 6.3.6 ESAOTE SpA
  • 6.3.7 Fujifilm Holdings Corporation
  • 6.3.8 GE HealthCare
  • 6.3.9 General Medical Merate SpA
  • 6.3.10 Hologic Inc.
  • 6.3.11 iCAD Inc.
  • 6.3.12 IMS Giotto SpA
  • 6.3.13 Incepto Medical Iberia
  • 6.3.14 Koninklijke Philips NV
  • 6.3.15 Kubtec Medical Imaging
  • 6.3.16 Metaltronica SpA
  • 6.3.17 Miwendo Solutions
  • 6.3.18 Palex Medical
  • 6.3.19 Planmed Oy
  • 6.3.20 Samsung Medison Co. Ltd.
  • 6.3.21 Sectra AB
  • 6.3.22 Shimadzu Corporation
  • 6.3.23 Siemens Healthineers AG

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment